Get the Stockscreener App
0.49
1.67%
-0.0083
After Hours:
.49
Lineage Cell Therapeutics Inc Stock (LCTX) Forecast
The Lineage Cell Therapeutics Inc (LCTX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $1.0741, representing a +119.21% increase from the current price of $0.49. The highest analyst price target is $1.1988, and the lowest is $0.9494.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month LCTX Price Target
Average 2.1531
(+339.41% Upside)
Is Lineage Cell Therapeutics Inc (LCTX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 54.86 | Neutral |
| STOCH(9,6) | 69.42 | Neutral |
| STOCHRSI(14) | 94.09 | Sell |
| MACD(12,26) | -0.011 | Buy |
| ADX(14) | 23.92 | Neutral |
| William %R | -16.01 | Sell |
| CCI(14) | 123.41 | Buy |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.446
Buy
|
0.4531
Buy
|
| MA20 |
0.4356
Buy
|
0.4543
Buy
|
| MA50 |
0.5149
Sell
|
0.4987
Sell
|
| MA100 |
0.5484
Sell
|
0.5694
Sell
|
| MA200 |
0.719
Sell
|
0.6977
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, LCTX could be considered a Moderate Sell, with 17 technical analysis indicators signaling 6 Buy signals, 8 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on LCTX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 54.86 indicates that LCTX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 69.42 indicates that LCTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 94.09 indicates that LCTX is oversold. This suggests that LCTX price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 23.92 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 123.41 indicates that LCTX is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term LCTX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Lineage Cell Therapeutics Inc financial reports and earnings history, Lineage Cell Therapeutics Inc (LCTX) stock could reach $1.3661 by 2030, $2.0735 by 2040 and $2.7483 by 2050. See the projected annual prices until 2050 of the Lineage Cell Therapeutics Inc stock below:
- Lineage Cell Therapeutics Inc (LCTX) is expected to reach an average price of $1.55 in 2035, with a high prediction of $1.8395 and a low estimate of $1.53. This indicates an $216.33% rise from the last recorded price of $0.49.
- Lineage Cell Therapeutics Inc (LCTX) stock is projected to chart a bullish course in 2040, with an average price target of $1.8635, representing an $280.31% surge from its current level. The forecast ranges from a conservative $1.677 to a sky-high $2.0735.
- Our analysts predict Lineage Cell Therapeutics Inc (LCTX) to jump 378.58% by 2045, soaring from $2.295 to an average price of $2.345, potentially reaching $2.423. While $2.295 is the low estimate, the potential upside is significant.
- Lineage Cell Therapeutics Inc (LCTX) stock is expected to climb by 2050, reaching an average of $2.53, a $416.33% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2.7483 and $2.51, respectively, highlighting the market's uncertainty.
Lineage Cell Therapeutics Inc Stock (LCTX) Year by Year Forecast
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2025
Lineage Cell Therapeutics Inc Stock (LCTX) is expected to reach an average price of $2.0253 in 2025, with a high prediction of $3.2546 and a low estimate of $0.7961. This indicates an +313.33% rise from the last recorded price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $1.0244 | $0.9494 | $1.1988 | +109.06% |
| June, 2025 | $1.1491 | $1.0048 | $1.1924 | +134.51% |
| July, 2025 | $1.1214 | $1.0404 | $1.2503 | +128.85% |
| August, 2025 | $1.1686 | $1.0815 | $1.3611 | +138.50% |
| September, 2025 | $1.3223 | $1.172 | $1.652 | +169.86% |
| October, 2025 | $1.6532 | $1.3225 | $1.8027 | +237.38% |
| November, 2025 | $1.9839 | $1.6125 | $2.2337 | +304.87% |
| December, 2025 | $2.4347 | $1.849 | $3.2546 | +396.88% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2026
The predicted value for Lineage Cell Therapeutics Inc (LCTX) in 2026 is set at an average of $2.5662. Estimates vary from a peak of $3.3568 to a trough of $1.7756, indicating an +423.72% surge from the present price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.5254 | $2.3954 | $3.3568 | +415.39% |
| February, 2026 | $2.5961 | $1.7756 | $2.8061 | +429.81% |
| March, 2026 | $2.5268 | $2.3263 | $2.8765 | +415.67% |
| April, 2026 | $2.6876 | $2.3675 | $3.1273 | +448.50% |
| May, 2026 | $2.9283 | $2.5378 | $3.2283 | +497.62% |
| June, 2026 | $2.989 | $2.8391 | $3.2285 | +510.00% |
| July, 2026 | $2.8499 | $2.6793 | $2.9993 | +481.60% |
| August, 2026 | $3.0205 | $2.515 | $3.0205 | +516.44% |
| September, 2026 | $2.8164 | $2.4909 | $3.0307 | +474.78% |
| October, 2026 | $2.5121 | $2.5019 | $2.8066 | +412.67% |
| November, 2026 | $2.2228 | $2.2028 | $2.8423 | +353.63% |
| December, 2026 | $2.9136 | $2.0335 | $2.9236 | +494.62% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Lineage Cell Therapeutics Inc (LCTX) is $2.1028, with a high forecast of $2.9438 and a low forecast of $1.2618. This indicates an +329.15% increase from the last price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.8043 | $1.8043 | $2.9438 | +268.23% |
| February, 2027 | $1.735 | $1.6395 | $1.9145 | +254.08% |
| March, 2027 | $1.5759 | $1.4909 | $1.8052 | +221.60% |
| April, 2027 | $1.8265 | $1.416 | $1.8964 | +272.76% |
| May, 2027 | $1.4572 | $1.3672 | $1.8517 | +197.39% |
| June, 2027 | $1.4881 | $1.3376 | $1.5581 | +203.69% |
| July, 2027 | $1.6088 | $1.4586 | $1.7884 | +228.32% |
| August, 2027 | $1.8594 | $1.5289 | $1.9992 | +279.48% |
| September, 2027 | $1.6903 | $1.6603 | $2.03 | +244.96% |
| October, 2027 | $1.541 | $1.521 | $1.7605 | +214.49% |
| November, 2027 | $1.4417 | $1.3417 | $1.5912 | +194.22% |
| December, 2027 | $1.5525 | $1.2618 | $1.6625 | +216.84% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2028
In 2028, Lineage Cell Therapeutics Inc (LCTX) is projected to reach an average price of $1.5493, with a high projection of $1.8246 and a low estimate of $1.2741. This indicates an +216.19% rise from the last price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.6932 | $1.4627 | $1.753 | +245.55% |
| February, 2028 | $1.3339 | $1.3039 | $1.7436 | +172.22% |
| March, 2028 | $1.6448 | $1.2741 | $1.8246 | +235.66% |
| April, 2028 | $1.6254 | $1.5454 | $1.7449 | +231.72% |
| May, 2028 | $1.6563 | $1.4656 | $1.7261 | +238.02% |
| June, 2028 | $1.657 | $1.5865 | $1.7968 | +238.16% |
| July, 2028 | $1.6277 | $1.5373 | $1.7577 | +232.18% |
| August, 2028 | $1.6285 | $1.4882 | $1.6485 | +232.35% |
| September, 2028 | $1.6192 | $1.5592 | $1.8177 | +230.45% |
| October, 2028 | $1.7799 | $1.5894 | $1.7799 | +263.24% |
| November, 2028 | $1.5707 | $1.5706 | $1.7901 | +220.56% |
| December, 2028 | $1.4414 | $1.4364 | $1.6561 | +194.17% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2029
The 2029 price forecast for Lineage Cell Therapeutics Inc Stock (LCTX) is $1.4817 on average, with a high prediction of $1.8667 and a low estimate of $1.0966. This represents an +202.38% increase from the previous price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.3823 | $1.3518 | $1.6219 | +182.10% |
| February, 2029 | $1.203 | $1.183 | $1.4526 | +145.50% |
| March, 2029 | $1.2937 | $1.2033 | $1.3537 | +164.01% |
| April, 2029 | $1.4543 | $1.1544 | $1.5243 | +196.80% |
| May, 2029 | $1.2352 | $1.0966 | $1.5645 | +152.08% |
| June, 2029 | $1.2959 | $1.2455 | $1.4355 | +164.47% |
| July, 2029 | $1.5266 | $1.3061 | $1.7064 | +211.54% |
| August, 2029 | $1.3974 | $1.3574 | $1.8667 | +185.19% |
| September, 2029 | $1.3403 | $1.2703 | $1.4276 | +173.54% |
| October, 2029 | $1.4871 | $1.2509 | $1.5921 | +203.48% |
| November, 2029 | $1.3875 | $1.3231 | $1.5024 | +183.17% |
| December, 2029 | $1.2098 | $1.2048 | $1.4438 | +146.90% |
Lineage Cell Therapeutics Inc Stock (LCTX) Price Forecast for 2030
Lineage Cell Therapeutics Inc Stock (LCTX) is expected to reach an average price of $1.5309 in 2030, with a high forecast of $2.1003 and a low forecast of $0.9614. This signifies an +212.42% surge from the last price of $0.49.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.2115 | $1.0899 | $1.3661 | +147.25% |
| February, 2030 | $1.3192 | $0.9614 | $1.3779 | +169.22% |
| March, 2030 | $1.4692 | $1.1583 | $1.6192 | +199.85% |
| April, 2030 | $1.8856 | $1.4296 | $2.1003 | +284.82% |
| May, 2030 | $1.2618 | $1.0121 | $1.871 | +157.52% |
| June, 2030 | $1.1894 | $1.1346 | $1.3077 | +142.73% |
| July, 2030 | $1.3444 | $1.155 | $1.4751 | +174.37% |
| August, 2030 | $1.4468 | $1.2758 | $1.6368 | +195.26% |
| September, 2030 | $1.2256 | $1.2219 | $1.5271 | +150.13% |
| October, 2030 | $1.3491 | $1.1688 | $1.4124 | +175.32% |
| November, 2030 | $1.3562 | $1.2609 | $1.4705 | +176.78% |
| December, 2030 | $1.3795 | $1.2816 | $1.5823 | +181.53% |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):